TriangleAtezolizumab (NCT05168163)
Atezolizumab trial for Locally Advanced Hepatocellular Carcinoma (NCT05168163). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with advanced hepatocellular carcinoma that progressed on first-line atezolizumab plus bevacizumab. Patients need Child-Pugh A liver function and are entering second-line treatment.
The idea: everyone receives daily oral cabozantinib or lenvatinib, which block growth-related enzymes. Randomization determines whether intravenous atezolizumab is added every three weeks to support immune attack. Treatment continues unless cancer progresses or toxicity becomes unacceptable. Researchers compare progression-free survival, overall survival, and safety.
This phase 2 study plans 122 patients. Wen Wee Ma leads for Academic and Community Cancer Research United; ten US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.